<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131445">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01390792</url>
  </required_header>
  <id_info>
    <org_study_id>112316</org_study_id>
    <nct_id>NCT01390792</nct_id>
  </id_info>
  <brief_title>Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)</brief_title>
  <official_title>Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-marketing surveillance study is to collect information on efficacy
      and safety for prophylactic administration of zanamivir in clinical practice in family or
      persons living with patients with influenza virus infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of incidence of adverse events in subjects treated with zanamivir</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of influenza virus infection</measure>
    <time_frame>11 days</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">622</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Subjects prescribed zanamivir</arm_group_label>
    <description>Subjects prescribed zanamivir during study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanamivir hydrate</intervention_name>
    <arm_group_label>Subjects prescribed zanamivir</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        &lt;Zanamivir prophylactic administration group&gt; Subjects meeting all of the following
        criteria and starting prophylactic administration of zanamivir

          -  family or persons living with patients with influenza virus infection

          -  subjects meeting any of the following criteria, elderly subjects ( 65 years old and
             over), subjects with chronic cardiac disease, with metabolic disease (diabetes, etc.)
             or with renal dysfunction

          -  unvaccinated persons during the applicable seasons

          -  subjects whose consent to write influenza diary was obtained

        &lt;Non-zanamivir prophylactic administration group&gt;

        - subjects meeting all of the above criteria and NOT starting prophylactic administration
        of zanamivir
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who meet the study population criteria

        Exclusion Criteria:

          -  Subjects with a history of hypersensitivity to the ingredients of zanamivir
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <reference>
    <citation>Keizo Matsumoto, Hideyuki Okano, Naomi Hasegawa, Ichiro Ohwaki, Shogo Inoshiri. Study on Preventive Effects of Zanamivir (Relenza) for Influenza. Medicine and Drug Journal. 2010;46(11):121-132.</citation>
  </reference>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 14, 2011</lastchanged_date>
  <firstreceived_date>July 7, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zanamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
